A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY TO EVALUATETHE EFFICACY AND SAFETY OFGANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES OF
ALZHEIMER’S DISEASE
You may be a candidate for a study of an investigational medication or placebo (inactive substance) in participants at risk of Alzheimer’s Disease.
Participant must have a reliable study partner.
Must be between ages of 60-80 without significant memory problems
• A single blood draw to test for blood-based biomarkers of Alzheimer’s Disease
• You would receive $50 for the BBBM (blood based biomarker) blood draw and information on whether you qualify for a study of those at risk or Alzheimer’s Disease.